James Falconer
Internal Medicine · Thomasville, GANPI 1295704641
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 232 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 10.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,158 and has fallen 62.3% since, to $437 in 2025.
Across 232 payments — averaging $15.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$379
- AstraZeneca$354
- Pfizer$304
- LEO Pharma Inc.$291
- GSK$267
- Amgen$266
- plus $2K from 32 others
Across 45 payments — averaging $14,339 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$645K
What the payments were for
- Food & beverage$3,607100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 23 | $379 |
| AstraZeneca | 24 | $354 |
| Pfizer | 25 | $304 |
| LEO Pharma Inc. | 12 | $291 |
| GSK | 14 | $267 |
| Amgen | 17 | $266 |
| Boehringer Ingelheim | 14 | $234 |
| Lilly USA, LLC | 17 | $176 |
| Astellas Pharma US Inc | 10 | $171 |
| Johnson & Johnson | 12 | $158 |
| AbbVie | 7 | $125 |
| Merck | 7 | $89 |
| Regeneron Healthcare Solutions, Inc. | 4 | $77 |
| Seqirus USA Inc | 4 | $75 |
| Sunovion Pharmaceuticals Inc. | 4 | $71 |
| Jazz Pharmaceuticals Inc. | 4 | $64 |
| Sanofi Pasteur Inc. | 4 | $53 |
| Bayer | 2 | $38 |
| Novartis | 2 | $36 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $36 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
| Grifols USA, LLC | 2 | $32 |
| Mallinckrodt Hospital Products Inc. | 2 | $32 |
| Insmed, Inc. | 2 | $28 |
| Incyte Corporation | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| Almatica Pharma LLC | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 3 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Organogenesis Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $16 |
| Abbott | 1 | $14 |
| Inari Medical, Inc. | 1 | $13 |
| Actelion Pharmaceuticals US, Inc. | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
| Valeritas, Inc. | 1 | $11 |
| Inogen, Inc. | 1 | $8 |
How this compares
$3,613 in reported general payments places this provider in the 85th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 242 | $242,917 |
| OzempicSemaglutide | 106 | $121,765 |
| JanuviaSitagliptin Phosphate | 49 | $64,761 |
| TrulicityDulaglutide | 61 | $63,562 |
| JardianceEmpagliflozin | 72 | $56,512 |
| Repatha SureclickEvolocumab | 75 | $44,502 |
| FarxigaDapagliflozin Propanediol | 34 | $29,541 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 91 | $27,777 |
| MounjaroTirzepatide | 26 | $27,368 |
| XareltoRivaroxaban | 27 | $27,306 |
| MyrbetriqMirabegron | 41 | $25,761 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $22,492 |
| Tresiba Flextouch U-100Insulin Degludec | 41 | $22,195 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 66 | $14,726 |
| LinzessLinaclotide | 24 | $14,512 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $304 | $246,943255 claims |
| Novo NordiskOzempic, Levemir | $379 | $125,019119 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $176 | $90,92987 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $234 | $67,72096 claims |
| MerckJanuvia | $89 | $64,76149 claims |
| GSKArexvy, Shingrix, Trelegy Ellipta, Breo Ellipta | $267 | $63,021190 claims |
| AstraZenecaFarxiga | $354 | $29,54134 claims |
| Johnson & JohnsonXarelto | $158 | $27,30627 claims |
| Astellas Pharma US IncMyrbetriq | $171 | $25,76141 claims |
| AbbVieLinzess | $125 | $14,51224 claims |
| Sanofi-aventis U.S. LLCLantus | $19 | $4,17415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Thomasville
- Michael GibsonSmyrna$2.2M
- Eduard FatakhovAlpharetta$376K
- Tracey HenryAtlanta$305K
- Sharon TuckettVilla Rica$265K
- Ebon BourneMarietta$242K
- Jennifer WoehlerSavannah$207K
- Julian HutchinsGreensboro$201K
- Brian PearlmanDalton$199K
- Scott ParryAtlanta$162K
- Jennifer GilliganAtlanta$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.